RxSight, Inc. (RXST)
| Market Cap | 295.47M |
| Revenue (ttm) | 134.48M |
| Net Income (ttm) | -38.94M |
| Shares Out | 41.27M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 531,324 |
| Open | 7.23 |
| Previous Close | 7.29 |
| Day's Range | 7.05 - 7.33 |
| 52-Week Range | 5.90 - 16.74 |
| Beta | 1.21 |
| Analysts | Hold |
| Price Target | 9.78 (+36.59%) |
| Earnings Date | May 6, 2026 |
About RXST
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be... [Read more]
Financial Performance
In 2025, RxSight's revenue was $134.48 million, a decrease of -3.89% compared to the previous year's $139.93 million. Losses were -$38.94 million, 41.8% more than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for RXST stock is "Hold." The 12-month stock price target is $9.78, which is an increase of 36.59% from the latest price.
News
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday,...
RxSight Transcript: 25th Annual Needham Virtual Healthcare Conference
Premium ophthalmic solutions are gaining traction, with strong surgeon endorsement and a shift toward deeper utilization within existing accounts. International expansion is a major growth focus, supported by regulatory progress and significant planned investments. LAL maintains strong pricing and margin stability.
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026
WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that ove...
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
ALISO VIEJO, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming 25th Annual Needham Virtual Healthcare Conference. Management...
RxSight Earnings Call Transcript: Q4 2025
Q4 2025 sales declined year-over-year due to lower LDD sales, but LAL revenue mix hit a record high and gross margins improved. 2026 guidance anticipates a modest revenue decline, with growth expected to rebound in the second half as commercial initiatives gain traction.
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,...
RxSight Transcript: 44th Annual J.P. Morgan Healthcare Conference
Achieved strong growth in procedures and sales, with a focus on premium adjustable IOLs that enhance patient outcomes and practice revenue. Organizational and commercial pivots are driving higher utilization, while international expansion and ongoing technical improvements position the business for further growth.
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following...
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,...
RxSight, Inc. Announces Chief Financial Officer Transition
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,...
RxSight Transcript: Piper Sandler 37th Annual Healthcare Conference
Management discussed recent market contraction, increased competition, and a strategic pivot to drive utilization and same-store sales. Financial guidance for 2025 was raised, with sequential growth expected in 2026. International expansion and operational realignment are key growth drivers.
RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
ALISO VIEJO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – November 20, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to...
RxSight Earnings Call Transcript: Q3 2025
Q3 revenue declined year-over-year but gross margin improved sharply due to a higher LAL mix. Guidance was narrowed with a focus on LAL volume growth and measured LDD placements, while international expansion and new clinical programs support long-term growth.
RxSight, Inc. Reports Third Quarter 2025 Financial Results
ALISO VIEJO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...
RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025
ALISO VIEJO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...
RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting
ALISO VIEJO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ca...
RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXST
LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violati...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In RxSight To Contact Him Directly To Discuss Their Options
DEADLINE NEXT WEEK: Berger Montague Advises RxSight, Inc. (NASDAQ: RXST) Investors to Contact the Firm Before September 22, 2025
PHILADELPHIA, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC, a nationally recognized securities litigation law firm, is investigating potential securities law violations involving RxSight, Inc...
RXST STOCK NEWS: RxSight, Inc. Investors Urged to Act by September 22 Court Deadline -- Contact BFA Law if You Suffered Losses
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Comp...
RXST SECURITIES NOTICE: Did RxSight, Inc. Mislead Investors? Contact BFA Law if You Lost Money on Your Investment
NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Comp...
RxSight Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
U.S. cataract surgery volumes declined early in the year, but premium IOL demand remained stable, with toric lenses favored for quality. Operational changes were made to improve new customer adoption, and international expansion is underway. The company continues to drive premium market growth, supported by strong clinical outcomes and favorable trends.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In RxSight To Contact Him Directly To Discuss Their Options If you purchased or acquired...
RXST LAWSUIT NOTICE: Lose Money on RxSight, Inc.? Contact BFA Law Prior to September 22 Legal Deadline (NASDAQ:RXST)
NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Comp...
RxSight Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Guidance was reduced due to market and internal challenges, with a focus on driving same-store sales and customer adoption through organizational changes. International expansion is underway but will contribute modestly until 2027, while new product enhancements are expected to support future growth.